NaturalVue® Multifocal Wins The Contact Lens Award for 2024
Celebrating Excellence in the UK Optical Industry
U.S.-based medical device company Visioneering Technologies, Inc. (ASX: VTI) (‘Visioneering’ or ‘The Company’) has won The Contact Lens Award of 2024, presented by The Optician Awards in the United Kingdom.
VTI is thrilled to announce that NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lenses, in partnership with our Authorized Distributor Positive Impact, has won The Contact Lens Award at the prestigious Optician Awards!
The Optician Awards celebrates excellence within the UK optical industry. With a legacy spanning over 30 years, these awards are among the most esteemed recognitions in British optics. The winners were unveiled on November 22 in London.
About the Contact Lens Award Nomination
The Contact Lens Award honors products and companies that have made a significant impact in the contact lens market over the past year. Judged by a panel of UK-based contact lens specialists, this category evaluates each nominee based on their innovation, contribution to market growth, and success in real-world practices.
The win recognizes the unique role that NaturalVue® Multifocal lenses have played in advancing contact lens technology, along with our commitment to supporting eye care professionals and providing products that exceed customer expectations. The release of the Year 1 results from the 3-year PROTECT (PROgressive Myopia Treatment Evaluation for NaturalVue® Multifocal Contact Lens) was instrumental in this nomination, showcasing our commitment to myopia management and improving patients’ quality of life. Dr. Juan Carlos Aragón, CEO and Executive Director of VTI, noted: “A special thanks to Positive Impact who put together an impressive and comprehensive submission for the award that among the highlights from our PROTECT study also included valuable feedback from NaturalVue fitters and patient experiences with the lenses. We are deeply honored to receive this coveted award and thank our partners for being part of our journey to bring innovative vision solutions to life!”
The PROTECT study, a 3-year, randomized, double-masked, controlled clinical trial, evaluates the safety and efficacy of NaturalVue® Multifocal lenses for managing myopia progression in children—a crucial area in pediatric eye care.
About Visioneering Technologies
Visioneering Technologies Inc. (ASX:VTI) is an innovative eye care company committed to redefining vision. A pioneer in presbyopia and myopia management, VTI merges advanced engineering with a relentless drive to achieve superior results for patients and practitioners. VTI’s flagship product is the NaturalVue® (etafilcon A) Enhanced Multifocal 1 Day Contact Lens, an extended depth of focus lens that the Company believes is one of the most significant innovations in the eye care industry in more than 20 years. For more information, please visit www.vtivision.com or call +1 844-884-5367, ext. 104.
MKT-VTI-PR89
